# Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-plus-chemotherapy-versus-chemotherapy-alone-for-first-line/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Jong‐Mu Sun,Lin Shen,Manish A. Shah,Peter C. Enzinger,Antoine Adenis,Toshihiko Doi,Takashi Kojima,Jean‐Philippe Metges,Zhigang Li,Sung‐Bae Kim,Byoung Chul Cho,Wasat Mansoor,Shau-Hsuan Li,Patrapim Sunpaweravong,María Maqueda,Eray Goekkurt,Hiroki Hara,Luís Carlos Moreira Antunes,Christos Fountzilas,Akihito Tsuji,Victor Castro Oliden,Qi Liu,Sukrut Shah,Pooja Bhagia,Ken Kato |
| Citations | 1,629 |
| DOI | 10.1016/s0140-6736(21)01234-4 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | http://repositorio.inen.pe:8080/handle/INEN/13 |
| OpenAlex ID | https://openalex.org/W3195935456 |
| PMID | 34454674 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Jong‐Mu Sun](https://scholariq.org/researchers/jong-mu-sun/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.